Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study.

Valenzise M, Nasso C, Scarfone A, Rottura M, Cafarella G, Pallio G, Visalli G, Di Prima E, Nasso E, Squadrito V, Wasniewska M, Irrera P, Arcoraci V, Squadrito F

Frontiers in pediatrics17 May 2023Cited by 12 (Europe PMC)

PMID37266535PMCIDPMC10229807DOI10.3389/fped.2023.1170025PepBankPUB-37266535

Download PDF PubMedAsk about this study

Jump to 5 results

Summary

IntroductionCentral precocious puberty (CPP) results from premature activation of hypothalamic-pituitary-gonadal axis, with the consequent increase of gonadotropin-releasing hormone (GnRH); GnRH agonists (GnRHa) represent the gold-standard therapy in children with CPP although their use might be responsible for pituitary GnRH receptors down-regulation, that in turn suppresses luteinizing hormone (LH) and follicle stimulating hormone (FSH) and blocks of gonadal sex hormones release. The most prescribed GnRHa in the clinical practice are leuprolide and triptorelin, whose use is generally safe and well tolerated; however, mild menopausal-like side effects could appear. The aim of the present study was to investigate and compare the efficacy and tolerability profile of leuprolide and triptorelin in CPP patients.Methods110 girls affected by CPP were enrolled in this retrospective study, carried out from 2018 to 2020. The enrolled patients received leuprolide (n = 48) or triptorelin (n = 62). Efficacy was investigated by the means of clinical parameters and radiological changes and side effects were also recorded to evaluate the possible relationship between the two GnRHa treatments and side effects appearance.ResultsAt baseline triptorelin patients had significantly higher LH and LH peak levels than leuprolide patients, whereas no significant difference in other patient characteristics was observed between the two groups. The leuprolide treatment lasted 971 days [790-1,171 days] while the duration of triptorelin administration was 792 days [760-1,003 days] (p < 0.001). Overall 46 (41.8%) of the studied patients reported mild menopausal-like symptoms: among these 27 were treated with triptorelin and 19 with leuprolide (p = 0.558). Patients treated with triptorelin, or leuprolide showed headache (27.4% vs. 16.7%), mood swings (12.9% vs. 16.7%), increased appetite (12.9% vs. 18.8%) and nausea (1.6% vs. 10.4%) respectively. Moreover, the onset of side effects appearance related to GnRHa therapy significantly reduces with the increase of the initial bone age (p = 0.038).ConclusionLeuprolide and triptorelin treatment appear to be effective and safe without significant difference between the two drugs in term of efficacy and tolerability, making both good options for treating CPP.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studySafety outcome
In girls with central precocious puberty, mild menopausal-like symptom frequency did not differ significantly between triptorelin and leuprolide.
In plain wordsIn girls with early puberty, mild menopausal-like symptom frequency did not differ significantly between triptorelin and leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMild menopausal-like symptoms
Study
n = 110
Comparator
Leuprolide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 792 days [760-1,003 days]As given in this study (human).
Measurements
Patients with menopausal-like symptoms
27 patients
triptorelin
Patients with menopausal-like symptoms
19 patients
leuprolide
Patients with menopausal-like symptoms
46 patients
all studied patients
Patients with menopausal-like symptoms
41.8%
all studied patients
Source sentences
Summary
Overall 46 (41.8%) of the studied patients reported mild menopausal-like symptoms: among these 27 were treated with triptorelin and 19 with leuprolide (p = 0.558).
2 context sentences(design, population, supporting numbers)
Summary · context
110 girls affected by CPP were enrolled in this retrospective study, carried out from 2018 to 2020.
Summary · context
The enrolled patients received leuprolide (n = 48) or triptorelin (n = 62).
Show in the study text Report a problemFND-3726653501
02HumanObservational studySafety outcome
In girls with central precocious puberty, headache occurred in 27.4% with triptorelin versus 16.7% with leuprolide.
In plain wordsIn girls with early puberty, headache occurred in 27.4% with triptorelin versus 16.7% with leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedHeadache
Study
n = 110
Comparator
Leuprolide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 792 days [760-1,003 days]As given in this study (human).
Measurements
Headache
27.4%
triptorelin
Headache
16.7%
leuprolide
Source sentences
Summary
Patients treated with triptorelin, or leuprolide showed headache (27.4% vs. 16.7%), mood swings (12.9% vs. 16.7%), increased appetite (12.9% vs. 18.8%) and nausea (1.6% vs. 10.4%) respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
110 girls affected by CPP were enrolled in this retrospective study, carried out from 2018 to 2020.
Summary · context
The enrolled patients received leuprolide (n = 48) or triptorelin (n = 62).
Show in the study text Report a problemFND-3726653502
03HumanObservational studySafety outcome
In girls with central precocious puberty, mood swings occurred in 12.9% with triptorelin versus 16.7% with leuprolide.
In plain wordsIn girls with early puberty, mood swings occurred in 12.9% with triptorelin versus 16.7% with leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedMood swings
Study
n = 110
Comparator
Leuprolide
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated · 792 days [760-1,003 days]As given in this study (human).
Measurements
Mood swings
12.9%
triptorelin
Mood swings
16.7%
leuprolide
Source sentences
Summary
Patients treated with triptorelin, or leuprolide showed headache (27.4% vs. 16.7%), mood swings (12.9% vs. 16.7%), increased appetite (12.9% vs. 18.8%) and nausea (1.6% vs. 10.4%) respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
110 girls affected by CPP were enrolled in this retrospective study, carried out from 2018 to 2020.
Summary · context
The enrolled patients received leuprolide (n = 48) or triptorelin (n = 62).
Show in the study text Report a problemFND-3726653503
04HumanObservational studySafety outcome
In girls with central precocious puberty, increased appetite occurred in 12.9% with triptorelin versus 18.8% with leuprolide.
In plain wordsIn girls with early puberty, increased appetite occurred in 12.9% with triptorelin versus 18.8% with leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedIncreased appetite
Study
n = 110
Comparator
Leuprolide
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 792 days [760-1,003 days]As given in this study (human).
Measurements
Increased appetite
12.9%
triptorelin
Increased appetite
18.8%
leuprolide
Source sentences
Summary
Patients treated with triptorelin, or leuprolide showed headache (27.4% vs. 16.7%), mood swings (12.9% vs. 16.7%), increased appetite (12.9% vs. 18.8%) and nausea (1.6% vs. 10.4%) respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
110 girls affected by CPP were enrolled in this retrospective study, carried out from 2018 to 2020.
Summary · context
The enrolled patients received leuprolide (n = 48) or triptorelin (n = 62).
Show in the study text Report a problemFND-3726653504
05HumanObservational studySafety outcome
In girls with central precocious puberty, nausea occurred in 1.6% with triptorelin versus 10.4% with leuprolide.
In plain wordsIn girls with early puberty, nausea occurred in 1.6% with triptorelin versus 10.4% with leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedNausea
Study
n = 110
Comparator
Leuprolide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 792 days [760-1,003 days]As given in this study (human).
Measurements
Nausea
1.6%
triptorelin
Nausea
10.4%
leuprolide
Source sentences
Summary
Patients treated with triptorelin, or leuprolide showed headache (27.4% vs. 16.7%), mood swings (12.9% vs. 16.7%), increased appetite (12.9% vs. 18.8%) and nausea (1.6% vs. 10.4%) respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
110 girls affected by CPP were enrolled in this retrospective study, carried out from 2018 to 2020.
Summary · context
The enrolled patients received leuprolide (n = 48) or triptorelin (n = 62).
Show in the study text Report a problemFND-3726653505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study.

Summary

Results from this study5

Version history

Subjects

Publication types

Keywords